187 related articles for article (PubMed ID: 15965967)
1. Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.
Tan EK; Cheah SY; Fook-Chong S; Yew K; Chandran VR; Lum SY; Yi Z
Am J Med Genet B Neuropsychiatr Genet; 2005 Aug; 137B(1):1-4. PubMed ID: 15965967
[TBL] [Abstract][Full Text] [Related]
2. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
3. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
4. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
5. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
[TBL] [Abstract][Full Text] [Related]
6. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
7. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
[TBL] [Abstract][Full Text] [Related]
8. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Senek M; Nyholm D; Nielsen EI
Sci Rep; 2020 Oct; 10(1):18057. PubMed ID: 33093598
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
12. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
[TBL] [Abstract][Full Text] [Related]
13. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.
Lee MS; Lyoo CH; Ulmanen I; Syvänen AC; Rinne JO
Neurosci Lett; 2001 Feb; 298(2):131-4. PubMed ID: 11163295
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
[TBL] [Abstract][Full Text] [Related]
15. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
16. Catechol-O-methyltransferase and Parkinson's disease.
Tai CH; Wu RM
Acta Med Okayama; 2002 Feb; 56(1):1-6. PubMed ID: 11873938
[TBL] [Abstract][Full Text] [Related]
17. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
[TBL] [Abstract][Full Text] [Related]
18. [Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function].
Horga de la Parte JF
Rev Neurol; 1999 Mar 1-15; 28(5):499-504. PubMed ID: 10229966
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
